Bicycle Therapeutics revenue was $10.39 m in FY, 2020
Bicycle Therapeutics revenue breakdown by business segment: 24.4% from Oxurion Agreement, 56.2% from Bioverativ Agreement and 19.4% from AstraZeneca Agreement
|FY, 2018||FY, 2017|
|Oxurion Agreement||$1.74 m||$815 k|
|Bioverativ Agreement||$4.01 m||$355 k|
|AstraZeneca Agreement||$1.39 m||$890 k|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.